Summary:
- Dupixent (dupilumab) has been approved by the European Union to treat a chronic inflammatory skin condition called atopic dermatitis in adults and adolescents.
- Dupixent is the first targeted medicine approved in the EU to treat this condition, which causes red, itchy rashes and can significantly impact a person's quality of life.
- This approval is an important milestone as it provides a new treatment option for patients with moderate-to-severe atopic dermatitis who have not responded well to other therapies.